Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes

BioRestorative Therapies, Inc.

By Julian Richard, Benzinga BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a notice of allowance for a patent application related to its metabolic ThermoStem® program. The Notice of Allowance signals the end of the examination process for the patent application. It indicates that the European Patent Office has determined that the ThermoStem® program is novel, non-obvious, and fully and particularly described in the patent application. The Notice of Allowance is a testament to BioRestorative’s commitment to innovation and advancing medical science through developing novel therapies utilizing adult stem cells. With this milestone, BioRestorative has made significant strides toward achieving its mission of developing and commercializing cell-based products and therapeutics for various metabolic conditions – such as diabetes and obesity – across key international markets. This patent will provide the company with protection for its proprietary ThermoStem® process, which is being developed for the treatment of metabolic syndrome. Metabolic syndrome is a cluster of conditions, such as obesity and increased cholesterol (fat) and glucose in the blood, that increase the risk of type 2 diabetes, heart disease and stroke. The ThermoStem® program harnesses the body’s ability to create new brown fat tissue from human brown adipose-derived stem cells. Pioneering research conducted by Biorestorative Therapies demonstrated that brown tissue burns rather than stores energy. Increased levels of brown tissue support weight loss by increasing metabolism and reducing sugar and fats in the blood. Thus, higher brown fat levels may address metabolic syndrome's significant effects. Obesity management is the subject of intense clinical development with Eli Lilly Co (NYSE: LLY) and Pfizer Inc (NYSE: PFE) looking to emulate the success of Semaglutide, marketed by Novo Nordisk A/S (NYSE: NVO) for the treatment of obesity and type 2 diabetes. “Our patent family for our ThermoStem® program continues to grow as we receive additional patent grants in key markets,” said Lance Alstodt, CEO of BioRestorative Therapies, commenting on the development. “We are committed to the development of ThermoStem® as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes. This patent, which covers a manufacturing process for ThermoStem® developed by BioRestorative’s scientists, enhances our ability to do so in European jurisdictions.” In addition to its metabolic program (ThermoStem®), BioRestorative Therapies is pioneering the use of a patient’s bone marrow cells to treat chronic lower back pain caused by degenerative disc disease. BRTX-100 is currently being evaluated as a non-invasive alternative to surgery in patients with degenerative chronic lower back pain, with results from the clinical study expected in March or April 2023. Visit https://www.biorestorative.com for more information on the company and its product candidates. This article originally appeared on Benzinga here. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

February 10, 2023 08:45 AM Eastern Standard Time

Quantum eMotion Sentry-Q platform to be used in Greybox Solutions digital therapeutics

Quantum eMotion Corp

Quantum eMotion CEO Francis Bellido joins Natalie Stoberman from the Proactive studio to discuss the latest Sentry-Q platform commercial agreement with Greybox Solutions, a Montreal-based health technology company specializing in innovative software development to improve patients' lives. Bellido says this partnership will enable Greybox's TakeCare digital therapeutic product to take advantage of QeM's Quantum-Safe cryptographic platform. Digital therapeutics refers to the use of technology-driven solutions, such as mobile apps, wearable devices, and telemedicine, to enhance patient outcomes by leveraging the benefits of technology such as patient health records convenience, accessibility, and real-time monitoring and feedback. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 10, 2023 08:04 AM Eastern Standard Time

Video

ResolutionRx announces research & development financing agreement with Radium Capital

RespireRx Pharmaceuticals

ResolutionRx Director Arnold Lippa joins Natalie Stoberman from the Proactive studio to discuss its recent letter of intent for financing with Radium Capital. ResolutionRx Ltd is a wholly owned subsidiary of RespireRx Pharmaceuticals. ResolutionRx was formed in Australia on Jan. 11, 2023 by RespireRx as an unlisted public company. RespireRx intends to contribute, sub-license, assign or otherwise make available to ResolutionRx, its cannabinoid drug development program subject to certain liabilities. ResolutionRx would then engage in the R&D associated with that program, initially for the development of a new formulation of dronabinol for use in a Phase 3 clinical trial and the filing of regulatory approval for the treatment of obstructive sleep apnea. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

February 10, 2023 07:56 AM Eastern Standard Time

Video

News Release

Valeo Pharma announces its Onstryv product receives public reimbursement in Quebec

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has obtained public reimbursement from the Quebec Government for its product Onstryv (safinamide). Saviuk told Proactive Health Canada approved Onstryv as an add-on therapy for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 09, 2023 02:03 PM Eastern Standard Time

Video

News Release

Hapbee announces Smart Sleep integration with Oura Ring

Hapbee Technologies Inc

Hapbee CEO Yona Shtern joined Proactive's Steve Darling to share news of an upgrade that combines biometric sleep data gathered from the Oura Ring and the features of Hapbee’s Smart Sleep Pad. Shtern told Proactive the creator of the Oura Ring has granted Hapbee use of its Application Programming Interface for the development of a sleep tracking plus sleep enhancement application. This will now allow the company to provide auto-prompts based on sleep cycles and track users' sleep improvements, he added. Shtern also talked about the feedback the company is hearing from professional athletes regarding its athlete and fitness professional outreach program. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 09, 2023 01:21 PM Eastern Standard Time

Video

New Research Finds Single Dose of Popular Antibiotic Given During Labor Significantly Reduced Risk of Maternal Death or Sepsis in Developing Countries

Society for Maternal-Fetal Medicine

Sepsis — a severe infection in the body that can lead to tissue damage, organ failure, and death — is among the top causes of maternal deaths worldwide, according to the World Health Organization (WHO). It is a life-threatening emergency that is largely preventable with early diagnosis and treatment and may disproportionately affect pregnant people in low- and middle-income countries. WHO has identified reducing maternal deaths, including death from sepsis, as a top global health priority. In a new study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™ — and published in the American Journal of Obstetrics & Gynecology — researchers will unveil findings that suggest that a single dose of azithromycin given to women planning a vaginal delivery significantly reduced the risk of maternal death or sepsis. The randomized control trial included 29,278 participants in eight sites of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Global Network for Women’s and Children’s Health Research in Africa (Democratic Republic of Congo, Kenya, and Zambia); Asia (Bangladesh, Pakistan, and two sites in India); and Latin America (Guatemala). Participants were randomized to receive either azithromycin — a popular, low-cost antibiotic used to treat a wide variety of bacterial infections and is on the WHO’s List of Essential Medicines — or a placebo. All participants were at least 28 weeks pregnant with a planned vaginal delivery at a healthcare facility. Overall, 14,590 people received azithromycin and 14,688 received a placebo. All participants were followed for 42 days after delivery, ensuring alignment with the WHO’s definition of maternal mortality, which includes death during pregnancy and within 42 days following delivery. Researchers found that a single dose of azithromycin, given orally, reduced the risk of maternal death or sepsis by 33 percent in women who delivered vaginally. In addition, researchers discovered several secondary findings, including fewer hospital readmissions and emergency visits among patients who received azithromycin. “International organizations identified severe maternal infections leading to death as a major global health problem, especially in developing counties, and there had been little progress over time” says the study’s lead author Alan Thevenet N. Tita, MD, PhD, a maternal-fetal medicine subspecialist at the University of Alabama at Birmingham Marnix E. Heersink School of Medicine, where he holds several positions, including associate dean for Global and Women’s Health; Mary Heersink Endowed Chair of Global Health and Director of the Global Health Institute; and director of the university-wide interdisciplinary Center for Women’s Reproductive Health. “We wanted to alleviate the burden of maternal infections in populations that give birth predominantly vaginally. Our research shows that just one dose of azithromycin may be a useful, low-cost intervention to reduce sepsis and attendant maternal deaths.” The study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Foundation for the National Institutes for Health (through a grant from the Gates Foundation). The complete study is also being published simultaneously in the New England Journal of Medicine today. To view the presentation of this abstract or other Pregnancy Meeting™ abstracts and events, visit the SMFM website or contact Karen Addis at karen@addispr.com or 301-787-2394. ### The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for maternal-fetal medicine subspecialists, who are obstetricians with additional training in high-risk pregnancies. SMFM represents more than 5,500 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to advance optimal and equitable perinatal outcomes for all people who desire and experience pregnancy. For more information, visit SMFM.org and connect with the organization on Facebook and Twitter. For the latest 2023 Annual Meeting news and updates, follow the hashtag #smfm23. Contact Details Addis Communications Karen Addis +1 301-787-2394 karen@addispr.com Society for Maternal-Fetal Medicine Kerri Wade +1 202-236-1780 kwade@smfm.org Company Website https://www.smfm.org/

February 09, 2023 10:15 AM Pacific Standard Time

Generation Hemp sees sales of Rowdy Rooster Hemp animal bedding soar 385%

Generation Hemp

Generation Hemp senior vice president Melissa Pagen joined Steve Darling from Proactive to discuss robust sales numbers for the company's Rowdy Rooster Hemp animal bedding product, ideal for small animals including rabbits, hamsters, reptiles, guinea pigs, and especially chickens. Pagen told Proactive Generation Hemp has seen a 385% year-over-year increase in sales. The company noted a big increase in the hemp product being used for chickens as the price of eggs skyrockets, resulting in many people turning to backyard chickens. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 09, 2023 01:00 PM Eastern Standard Time

Video

New Research Finds that People Who Use Cannabis Early in Pregnancy Are At Increased Risk of Poor Pregnancy Outcomes

Society for Maternal-Fetal Medicine

As more states legalize marijuana for recreational use, researchers are looking into the potential health effects of cannabis use during pregnancy. In a new study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™ — and published in the American Journal of Obstetrics & Gynecology — researchers will unveil findings that suggest that using cannabis in the first six to 14 weeks of pregnancy is associated with poor pregnancy outcomes that are closely related to the function of the placenta. The placenta plays an important role during pregnancy, including providing an infant with oxygen and nutrients, removing harmful waste and carbon dioxide, and producing hormones that help a baby grow. Medicine, drugs, alcohol and nicotine can transfer from a pregnant person’s bloodstream to their baby through the placenta. Researchers analyzed urine samples collected during the Nulliparous Mothers-to-Be (nuMoM2b) study, a large, diverse multicenter cohort of pregnant people. Of the 10,038 nuMoM2b participants, researchers included data from 9,257 pregnant people in their first trimester of pregnancy. After doing a drug screen for marijuana, researchers discovered that 540 (5.8 percent) tested positive for marijuana, meaning those individuals most likely used cannabis in the first six to 14 weeks of their pregnancy. The study found that using cannabis early in pregnancy is associated with adverse pregnancy outcomes related to the placenta, such as poor fetal growth, stillbirth, and an increased risk of developing high blood pressure during pregnancy. “We wanted to look specifically at cannabis use early in pregnancy because that’s when the placenta is forming, and a lot of information we currently have indicates that cannabis use does affect the placenta,” says the study’s lead author Torri D. Metz, MD, MS, a maternal-fetal medicine subspecialist and associate professor of obstetrics and gynecology at the University of Utah Health in Salt Lake City. “With recreational marijuana use becoming legal in more states, we need better data because patients are interested in understanding the risk of cannabis use in pregnancy so they can make an informed decision.” The next step, say researchers, is to look at ongoing cannabis use during pregnancy and whether “the window of exposure” matters. To view the presentation of this abstract or other Pregnancy Meeting™ abstracts and events, visit the SMFM website or contact Karen Addis at karen@addispr.com or 301-787-2394. ### About the Society for Maternal-Fetal Medicine The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for maternal-fetal medicine subspecialists, who are obstetricians with additional training in high-risk pregnancies. SMFM represents more than 5,500 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to advance optimal and equitable perinatal outcomes for all people who desire and experience pregnancy. For more information, visit SMFM.org and connect with the organization on Facebook and Twitter. For the latest 2023 Annual Meeting news and updates, follow the hashtag #smfm23. Contact Details Addis Communications Karen Addis +1 301-787-2394 karen@addispr.com Society for Maternal-Fetal Medicine Kerri Wade +1 202-236-1780 kwade@smfm.org Company Website https://www.smfm.org/

February 09, 2023 08:36 AM Pacific Standard Time

ImmuPharma expects new Lupozor study to begin in H2 2023

ImmuPharma PLC

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy spoke to Thomas Warner at Proactive's London studio after announcing that its partner Avion Pharmaceuticals is to launch an adaptive phase II/III clinical study on Lupuzor, the former’s discovery and putative treatment for systemic lupus erythematosus (SLE). McCarthy reveals the reasons for choosing the particular type of study and explains what else investors can expect from ImmuPharma during 2023. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 09, 2023 06:07 AM Eastern Standard Time

Video

1 ... 160 161 162 163 164 ... 305